|
||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
|
||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Overview
This program is designed to provide a critical update to physicians on the best measures currently available to prevent meningococcal disease in their patients. This includes the latest evidence-based research on specific serotypes of meningococcus and the specific vaccines directed against them, the efficacy and safety of these vaccines, the most recent guidelines of the CDC and ACIP, and the most effective means of communicating with their patients and achieving the highest rates of vaccination possible against this disease.
Objectives
Identify patient groups at high risk for meningococcal infection and employ effective screening procedures and routine review of immunization records to ensure appropriate vaccination rates
Understand the correspondence between the strains or serogroups of N meningitidis prevalent in the U.S. and the characteristics such as vaccine class (polysaccharide, conjugate), specificity for one or more strains, efficacy, and safety of the currently approved vaccines
Faculty
Lee H. Harrison, MD
Professor and Head
Infectious Diseases Epidemiology Research Unit
University of Pittsburgh
Pittsburgh, PA
Richard G. Judelsohn, MD
Managing Partner
Buffalo Pediatric Associates
Medical Director
Erie County Health Department
Buffalo, NY
Overview
This CME activity will provide primary care clinicians with the tools needed to better understand rotavirus prevention and management. The goal of this educational activity is to provide primary care clinicians with the education to work toward decreasing the overall impact of rotavirus in the US.
Objectives
Expand clinician knowledge of the safety and efficacy of the rotavirus vaccine and risk benefits and increase the level of effective management of rotavirus for those patients who have not received the vaccine
Describe the ages at which it is appropriate to administer the rotavirus vaccine and name one method to help prevent rotavirus transmission within the home setting
Faculty
Penelope H. Dennehy, MD
Director, Pediatric Infectious Diseases
Hasbro ChildrenŐs Hospital
Professor of Pediatrics
Warren Alpert Medical School of Brown University
Rhode Island Hospital
Providence, RI
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. As HPV is most prevalent among young, sexually active individuals, prevention through prophylactic HPV vaccination of preadolescents and adolescents before they become sexually active provides the maximum health benefit. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection, provide an update on the safety and efficacy of HPV vaccines, including recent data to expand the benefits of vaccination, and address common barriers to implementing HPV vaccination into pediatric practice.
Objectives
Describe the health consequences associated with HPV infection
Discuss the benefits of HPV vaccination with adolescent patients and their parents
Faculty
J. Dennis Fortenberry, MD, MS
Professor of Pediatrics
Indiana University School of Medicine
Indianapolis, IN
Lawrence J. D'Angelo, MD, MPH
Chief, Division of Adolescent and Young Adult Medicine
Children's National Medical Center
Washington, DC
Overview
This educational activity is designed to give clinicians an overview of asthma as a heterogeneous disease and its implication for individual treatment. It will also provide guidance for using the NAEPP EPR 3 guidelines as part of a comprehensive, long-term asthma management plan custom tailored for the needs of each individual patient. NAEPP EPR 3 domains of asthma control include measures of assessment and monitoring; control of factors that contribute to asthma severity; pharmacologic therapy; and education for a partnership in asthma.
Objectives
Understand why the updated NAEPP EPR 3 guidelines are useful in treatment of pediatric patients with asthma and name the 2 domains for assessing asthma control
Name the symptoms of asthma and understand how to effectively monitor their asthma patients by naming the specific time intervals to ensure that patients maintain optimal control
Faculty
Don Bukstein, MD
Assistant Clinical Professor
Department of Pediatrics and Family Practice
University of Wisconsin
Madison, WI
Overview
Using the latest evidence related to the safety, efficacy, and tolerability profiles of current treatment options, combined with improved skills in recognition and diagnosis, physicians can be poised to deliver up-to-date, evidence-based care to their patients with ADHD.
Objectives
Recognize the importance of early identification of symptoms for improved diagnosis and treatment of children and adolescents with ADHD
Compare and contrast the current treatment options for children and adolescents with ADHD and develop individualized management strategies for each patient
Faculty
David Baron, MSEd, DO
Professor and Chair, Department of Psychiatry and Behavioral Sciences, Temple University School of Medicine
Philadelphia, PA
Frank A. Lopez, MD
Neuro-Developmental Pediatrician
Director, ChildrenŐs Developmental Center
Winter Park, FL